Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13917933 | 0.88 | CD274 (0.49) | PTPN1CD274SMN1; SMN2BCHEL3MBTL1 | |
| SCHEMBL12082741 | 0.81 | PTPN1 (0.51) | PTPN1SMN1; SMN2BCHEALDH1A1KDM4E | |
| SCHEMBL13114968 | 0.78 | CD274 (0.48) | CD274 | |
| SCHEMBL17955664 | 0.76 | CD274 (0.46) | PTPN1CD274SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL4599207 | 0.74 | CD274 (0.49) | PTPN1CD274SMN1; SMN2BCHEL3MBTL1 | |
| SCHEMBL3188344 | 0.73 | CYP1A2 (0.55) | CD274SMN1; SMN2ALDH1A1KDM4EPOLB | |
| SCHEMBL28915772 | 0.73 | APLNR (0.57) | PTPN1SMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL8880359 | 0.73 | APLNR (0.78) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL12309456 | 0.72 | CD274 (0.48) | CD274 | |
| SCHEMBL10781561 | 0.72 | MEN1 (0.55) | SMN1; SMN2BCHEALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816360-B2 | Microsomal triglyceride transfer protein (MTP) inhibitors, used for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and non-insulin dependent diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | MEERPOEL LIEVEN | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | PNLIP, LPL, APOB | PTPN1 1116/4885CD274 4365/4885SMN1; SMN2 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.